Raymond Cross, MD
Gastroenterology · Baltimore, MDNPI 1447214507
Payments from drug & device makers
Across 663 payments — averaging $1808.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$335K
- Janssen Research & Development, LLC$235K
- Gilead$195K
- AbbVie$152K
- Johnson & Johnson$103K
- Pfizer$47K
- plus $133K from 32 others
Across 10 payments — averaging $1264.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$11K
- AbbVie$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 96 | $334,885 |
| Janssen Research & Development, LLC | 5 | $235,003 |
| Gilead | 39 | $194,612 |
| AbbVie | 170 | $152,074 |
| Johnson & Johnson | 129 | $102,539 |
| Pfizer | 66 | $47,268 |
| Eli Lilly | 8 | $38,697 |
| Janssen Scientific Affairs, LLC | 51 | $24,426 |
| E.r. Squibb & Sons, L.L.C. | 18 | $20,163 |
| Genentech, Inc. | 4 | $11,950 |
| F. Hoffmann-la Roche AG | 3 | $11,100 |
| Hexal AG | 2 | $9,360 |
| Bristol Myers Squibb | 29 | $7,691 |
| Pharmacosmos Therapeutics Inc. | 1 | $3,340 |
| Samsung Bioepis Co., Ltd. | 3 | $2,300 |
| Janssen Global Services, LLC | 1 | $1,515 |
| Fresenius Kabi USA, LLC | 1 | $610 |
| Sebela Pharmaceuticals Inc. | 1 | $500 |
| Medtronic | 1 | $146 |
| Mallinckrodt Hospital Products Inc. | 4 | $111 |
| Digestive Care, Inc. | 3 | $103 |
| Lilly USA, LLC | 4 | $94 |
| Boston Scientific | 1 | $71 |
| Madrigal Pharmaceuticals | 2 | $53 |
| Amgen | 2 | $52 |
| Shionogi Inc | 3 | $51 |
| UCB, Inc. | 2 | $41 |
| Celltrion USA Inc. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 2 | $33 |
| Sanofi | 1 | $30 |
| Eisai Inc. | 1 | $27 |
| AstraZeneca | 1 | $23 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
| Sandoz | 1 | $17 |
| Mirum Pharmaceuticals, Inc. | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
How this compares
$1,199,023 in reported general payments places this provider in the 95th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Baltimore
- Kenolisa OnwuemeBaltimore$4.5M
- Paul ThuluvathBaltimore$3.6M
- Marcia CantoBaltimore$1.6M
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$1.1M
- Mouen KhashabBaltimore$670K
- Alyssa ParianBaltimore$638K
- Aline Charabaty PishvaianBaltimore$631K
- James HamiltonBaltimore$307K
- Niraj JaniBaltimore$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.